nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2018-22-2-30-38nefr-349Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПОРАЖЕНИЕ ПОЧЕК ПРИ ПРЕЭКЛАМПСИИ: ВЗГЛЯД НЕФРОЛОГА (ОБЗОР ЛИТЕРАТУРЫ)RENAL INJURY IN PREECLAMPSIA: THE VIEW OF NEPHROLOGIST (LITERATURE REVIEW)МеркушеваЛ. И.MerkushevaL. I.

Меркушева Людмила Игоревна, кандидат медицинских наук, врач-нефролог 

117197, Москва, ул. Академика Опарина, д. 4. 

 Liudmila I. Merkusheva, MD, PhD 

117197, Moscow, ac. Oparina str. 4

milka0013@mail.ruКозловскаяН. ЛKozlovskayaN. L.

Козловская Наталья Львовна - профессор, доктор медицинских наук, кафедра внутренних, профессиональных болезней и пульмонологии медико-профилактического факультета 

119991, Москва, ул. Трубецкая, д. 8, стр. 2. 

Natalia L. Kozlovskaya, Prof. MD, PhD, DSci, Department of Internal and Occupational Medicine, Faculty of Preventive Medicine 

119991, Moscow, Trubetskaya, 8-2 str.

nkozlovskaya@yandex.ruНациональный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. КулаковаРоссияNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academical V.I. Kulakov of Ministry of Healthcare of Russian FederationRussian FederationПервый Московский государственный медицинский университет им. И. М. СеченоваРоссияFirst Moscow State Medical Sechenov UniversityRussian Federation2018120220202223038Copyright © Меркушева Л.И., Козловская Н.Л., 20202020Меркушева Л.И., Козловская Н.Л.Merkusheva L.I., Kozlovskaya N.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/349

Рост интереса нефрологов к проблеме поражения почек при преэклампсии (ПЭ) обусловлен её высокой распространенностью (2–14% от всех беременностей) и непредсказуемым исходом. Патогенез поражения почек при ПЭ мало изучен, однако, установлена роль дисбаланса про- и антиангиогенных факторов – VEGF и sFlt-1 – как одного из важнейших патогенетических механизмов, лежащих в основе развития ПЭ. В статье приводятся современные данные о патогенезе и почечных проявлениях ПЭ на разных сроках её развития в сопоставлении с маркерами плацентарного ангиогенеза. Обсуждается роль дисбаланса системы sFlt-1/VEGF в формировании протеинурии, артериальной гипертензии и ренальной дисфункции при ПЭ, а также «ранней» ПЭ как фактора риска развития хронической болезни почек (ХБП). 

The growing interest of nephrologists in the problem of kidney injury in preeclampsia is due to its high prevalence (2–14% of all pregnancies) and unpredictable outcome. The pathogenesis of kidney injury in PE is poorly known, however, the role of imbalance of pro- and anti-angiogenic factors – VEGF and sFlt-1 – has been established as one of the most important pathogenetic mechanisms underlying the development of PE. The article presents modern data on the pathogenesis and renal manifestations of PE at different times of its development in comparison with markers of placental angiogenesis. The role of the imbalance of the sFlt-1 / VEGF system in the formation of proteinuria, arterial hypertension and renal dysfunction in PE is discussed, as well as the role of “early” PE as a risk factor for the development of chronic kidney disease.

преэклампсиягломерулярное поражениесосудистый эндотелиальный фактор роста (VEGF)растворимая fms-подобная тирозинкиназа-1 (sFlt-1)подоцитурияпротеинурияскорость клубочковой фильтрацииартериальная гипертензияpreeclampsiaglomerular injuryvascular endothelium growth factor (VEGF)soluble fms-like tyrosine kinase-1 receptors (sFlt-1)podocyturiaproteinuriaglomerular filtration rateblood pressureReferencesJames PR, Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart 2004; 90: 1499–1504. doi.org/10.1136/hrt.2004.035444James PR, Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart 2004; 90: 1499–1504. doi.org/10.1136/hrt.2004.035444Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nature Clin Pract Nephrol 2005; 1(2): 98–114. doi.org/10.1038/ncpneph0035Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nature Clin Pract Nephrol 2005; 1(2): 98–114. doi.org/10.1038/ncpneph0035Нertig A, Watnick S, Strevens H. et al. How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clin Pract Nephrol 2008; 4 (9): 503—509. doi.org/10.1038/ncpneph0880Нertig A, Watnick S, Strevens H. et al. How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clin Pract Nephrol 2008; 4 (9): 503—509. doi.org/10.1038/ncpneph0880Levine RJ, Maynard SE, Quan C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683. doi.org/10.1056/NEJMoa031884Levine RJ, Maynard SE, Quan C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683. doi.org/10.1056/NEJMoa031884Maynard SE, Min JY, Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658. doi.org/10.1172/JCI17189Maynard SE, Min JY, Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658. doi.org/10.1172/JCI17189Karumanchi SA, Maynard SE, Stillman IE et al. Preeclampsia: a renal perspective. Kidney Intern 2005; 67: 2101–2113. doi.org/10.1111/j.1523-1755.2005.00316.xKarumanchi SA, Maynard SE, Stillman IE et al. Preeclampsia: a renal perspective. Kidney Intern 2005; 67: 2101–2113. doi.org/10.1111/j.1523-1755.2005.00316.xPhyllis A. Preeclampsia: a «nephrocentric» view. Adv Chronic Kidney Rev 2013; 20(3):280–286 doi.org/10.1053/j.ackd.2013.01.013Phyllis A. Preeclampsia: a «nephrocentric» view. Adv Chronic Kidney Rev 2013; 20(3):280–286 doi.org/10.1053/j.ackd.2013.01.013Тареева ИЕ. Нефрология: Руководство для врачей. Медицина, М., 2000; 464–473 [Tareeva I.E. Rukovodstvo dlya vrachej. Medicina, M., 2000; 464–473]Тареева ИЕ. Нефрология: Руководство для врачей. Медицина, М., 2000; 464–473 [Tareeva I.E. Rukovodstvo dlya vrachej. Medicina, M., 2000; 464–473]Fisher KA, Ahuja S, Luger AM et al. Nephrotic proteinuria with preeclampsia. Am J Obstet Gynecol 1977; 129: 643–646. doi.org/10.1016/0002-9378(77)90646-9Fisher KA, Ahuja S, Luger AM et al. Nephrotic proteinuria with preeclampsia. Am J Obstet Gynecol 1977; 129: 643–646. doi.org/10.1016/0002-9378(77)90646-9Cohen AW, Burton NG. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus. Obstet Gynaecol 1979; 53: 130–134Cohen AW, Burton NG. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus. Obstet Gynaecol 1979; 53: 130–134Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Влияние дисбаланса плацентарных факторов ангиогенеза на клинические проявления «ранней» и «своевременной» преэклампсии. Нефрология и диализ 2013; 15(3): 206–215 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Vliyanie disbalansa platsentarnykh faktorov angiogeneza na klinicheskie proyavleniya «rannej» i «svoevremennoj» preehklampsii. Nephrology and Dialysis 2013; 15(3):206–215]Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Влияние дисбаланса плацентарных факторов ангиогенеза на клинические проявления «ранней» и «своевременной» преэклампсии. Нефрология и диализ 2013; 15(3): 206–215 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Vliyanie disbalansa platsentarnykh faktorov angiogeneza na klinicheskie proyavleniya «rannej» i «svoevremennoj» preehklampsii. Nephrology and Dialysis 2013; 15(3):206–215]Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Дисбаланс плацентарных факторов ангиогенеза и клинические особенности «ранней» и «своевременной» преэклампсии. Взгляд нефролога. Архив акушерства и гинекологии им. В.Ф.Снегирева 2014; 1:13–21 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Disbalans platsentarnykh faktorov angiogeneza i klinicheskie osobennosti «rannej» i «svoevremennoj» preehklampsii. Vzglyad nefrologa. V.F.Snegirev Archives of Obstetrics and Gynecology 2014; 1:13–21]Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ и др. Дисбаланс плацентарных факторов ангиогенеза и клинические особенности «ранней» и «своевременной» преэклампсии. Взгляд нефролога. Архив акушерства и гинекологии им. В.Ф.Снегирева 2014; 1:13–21 [Kozlovskaya NL, Merkusheva LI, Kirsanova TV i dr. Disbalans platsentarnykh faktorov angiogeneza i klinicheskie osobennosti «rannej» i «svoevremennoj» preehklampsii. Vzglyad nefrologa. V.F.Snegirev Archives of Obstetrics and Gynecology 2014; 1:13–21]Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18: 152–161. doi.org/10.1038/ki.1980.124Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18: 152–161. doi.org/10.1038/ki.1980.124Moran P, Baylis PH, Lindheimer MD. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003;14: 648–652. doi.org/10.1097/01.ASN.0000051724.66235.E0Moran P, Baylis PH, Lindheimer MD. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003;14: 648–652. doi.org/10.1097/01.ASN.0000051724.66235.E0National Kidney Foundation. Kidney Disease Outcome Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2): 1–180. DOI: 10.1053/j. ajkd.2006.12.005National Kidney Foundation. Kidney Disease Outcome Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2): 1–180. DOI: 10.1053/j. ajkd.2006.12.005Smith МС, Moran Р, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG: An International Journal of Obstetrics & Gynaecology 2008; 115(1): 109–112. doi.org/10.1111/j.1471-0528.2007.01529.xSmith МС, Moran Р, Ward MK, Davison JM. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG: An International Journal of Obstetrics & Gynaecology 2008; 115(1): 109–112. doi.org/10.1111/j.1471-0528.2007.01529.xSchaffer N, Dill L, Cadden J. Uric acid clearance in normal pregnancy and preeclampsia. J Clin Invest 1943; 22:201–206. doi.org/10.1172/JCI101383Schaffer N, Dill L, Cadden J. Uric acid clearance in normal pregnancy and preeclampsia. J Clin Invest 1943; 22:201–206. doi.org/10.1172/JCI101383Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007;18:2281–2284. doi.org/10.1681/ASN.2007020255Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007;18:2281–2284. doi.org/10.1681/ASN.2007020255Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestation and molecular mechanisms. Nephron Clin Pract 2007;106:72–81. doi.org/10.1159/000101801Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestation and molecular mechanisms. Nephron Clin Pract 2007;106:72–81. doi.org/10.1159/000101801Strevens H, Wide-Swensson D, Hansen A еt al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. Br J Obst Gynecol 2003;110: 831–836. doi.org/10.1111/j.1471-0528-.2003.02162.xStrevens H, Wide-Swensson D, Hansen A еt al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. Br J Obst Gynecol 2003;110: 831–836. doi.org/10.1111/j.1471-0528-.2003.02162.xGaber LW, Spargo BH: Pregnancy-induced nephropathy: The significance of focal segmental glomerulosclerosis. Am J Kidney Dis 1987; 9: 317–323. doi.org/10.1016/S0272-6386-(87)80129-4Gaber LW, Spargo BH: Pregnancy-induced nephropathy: The significance of focal segmental glomerulosclerosis. Am J Kidney Dis 1987; 9: 317–323. doi.org/10.1016/S0272-6386-(87)80129-4Heaton JM, Turner DR. Persistent renal damage following pre-eclampsia: A renal biopsy study of 13 patients. J Pathol1985; 147: 121–126. doi.org/10.1002/path.1711470207Heaton JM, Turner DR. Persistent renal damage following pre-eclampsia: A renal biopsy study of 13 patients. J Pathol1985; 147: 121–126. doi.org/10.1002/path.1711470207Saritas T, Moeller MJ. Pre-eclamsia, podocyturia and the role of parietal epithelial cells. J Nat Rev Nephrol 2014;10:615– 616.doi:10.1038/nrneph.2014.163Saritas T, Moeller MJ. Pre-eclamsia, podocyturia and the role of parietal epithelial cells. J Nat Rev Nephrol 2014;10:615– 616.doi:10.1038/nrneph.2014.163Simon M, Grone H-J, Johren O et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 37:24–250. doi.org/10.1152/ajprenal.1995.268.2.F240Simon M, Grone H-J, Johren O et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 37:24–250. doi.org/10.1152/ajprenal.1995.268.2.F240Nakagawa T, Lan HY, Zhu HJ et al. Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells. Am J Physiol Renal Physiol 2004; 287(4): 658–664. doi.org/10.1152/ajprenal.00040.2004Nakagawa T, Lan HY, Zhu HJ et al. Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells. Am J Physiol Renal Physiol 2004; 287(4): 658–664. doi.org/10.1152/ajprenal.00040.2004Kearney JB, Kappas NC, Ellerstrom C et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004; 103(12): 4527 – 4535. doi.org/10.1182/blood-2003-07-2315Kearney JB, Kappas NC, Ellerstrom C et al. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004; 103(12): 4527 – 4535. doi.org/10.1182/blood-2003-07-2315Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39(6):1095–1100. doi.org/10.1161/01.HYP.0000018588.56950.7ALi B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39(6):1095–1100. doi.org/10.1161/01.HYP.0000018588.56950.7ASuga S, Kim Y, Joly A et al. Vascular endothelial grown factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney International 2001;60: 1297–1308. doi.org/10.1046/j.1523-1755.2001.00935.xSuga S, Kim Y, Joly A et al. Vascular endothelial grown factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney International 2001;60: 1297–1308. doi.org/10.1046/j.1523-1755.2001.00935.xEremina V, Jefferson A, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–1139. doi.org/10.1056/NEJMoa0707330Eremina V, Jefferson A, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–1139. doi.org/10.1056/NEJMoa0707330Bollee, G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2008; 24: 682–685. doi.org/10.1093/ndt/gfn657 31.Bollee, G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2008; 24: 682–685. doi.org/10.1093/ndt/gfn657 31.Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int 2005; 67:1668–1671. doi.org/10.1111/j.1523-1755-.2005.00260.xBallermann BJ. Glomerular endothelial cell differentiation. Kidney Int 2005; 67:1668–1671. doi.org/10.1111/j.1523-1755-.2005.00260.xMuller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J of Pregnancy 2011; 2011: 6 pages. Article ID 176973. doi.org/10.1155/2011/176973Muller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J of Pregnancy 2011; 2011: 6 pages. Article ID 176973. doi.org/10.1155/2011/176973Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in Perinatology 2009;33(3):130–137. doi. org/10.1053/j.semperi.2009.02.010Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in Perinatology 2009;33(3):130–137. doi. org/10.1053/j.semperi.2009.02.010Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434. doi. org/10.1056/NEJMoa021491Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434. doi. org/10.1056/NEJMoa021491Robinson E, Matulonis U, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial grown factor receptor inhibitor. Clinical Journal of the American Society of Nephrology 2010; 5(3): 477–483. doi. org/10.2215/CJN.08111109Robinson E, Matulonis U, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial grown factor receptor inhibitor. Clinical Journal of the American Society of Nephrology 2010; 5(3): 477–483. doi. org/10.2215/CJN.08111109Patel TV, Morgan GA, Demetri GD et al. A preeclampsialike syndrome characterized by reversible hypertension and proteinuria indused by the multitargeted kinase inhibitors sunitinib and soferenib. Journal of the National Cancer Institute 2008;100 (4):282–284. doi.org/10.1093/jnci/djm311Patel TV, Morgan GA, Demetri GD et al. A preeclampsialike syndrome characterized by reversible hypertension and proteinuria indused by the multitargeted kinase inhibitors sunitinib and soferenib. Journal of the National Cancer Institute 2008;100 (4):282–284. doi.org/10.1093/jnci/djm311Yang R, Ogasawara AK, Zioncheck TF et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002;39(3):815–820. doi.org/10.1161/hy0302.105398Yang R, Ogasawara AK, Zioncheck TF et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002;39(3):815–820. doi.org/10.1161/hy0302.105398Okuda Y, Tsurumaru K, Suzuki S et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sciences 1998; 63(6):477–484.doi.org/10.1016/S0024-3205(98)00296-3Okuda Y, Tsurumaru K, Suzuki S et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sciences 1998; 63(6):477–484.doi.org/10.1016/S0024-3205(98)00296-3Зозуля ОВ, Рогов ВА, Пятакова НВ, Тареева ИЕ. Оксид азота: роль в развитии осложнений беременности и в их профилактике у женщин с гипертонической болезнью и хроническим гломерулонефритом. Терапевтический архив 1997; 69(6):17–21 [Zozulya OV, Rogov VA, Pyatakova NV, Tareeva IE. Oksid azota: rol' v razvitii oslozhnenij beremennosti i v ih profilaktike u zhenshchin s gipertonicheskoj bolezn'yu i hronicheskim glomerulonefritom. Terapevticheskij arhiv 1997;69(6):17–21]Зозуля ОВ, Рогов ВА, Пятакова НВ, Тареева ИЕ. Оксид азота: роль в развитии осложнений беременности и в их профилактике у женщин с гипертонической болезнью и хроническим гломерулонефритом. Терапевтический архив 1997; 69(6):17–21 [Zozulya OV, Rogov VA, Pyatakova NV, Tareeva IE. Oksid azota: rol' v razvitii oslozhnenij beremennosti i v ih profilaktike u zhenshchin s gipertonicheskoj bolezn'yu i hronicheskim glomerulonefritom. Terapevticheskij arhiv 1997;69(6):17–21]Sugimoto H, Hamanog Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry 2003;278(15):12605–12608. doi.org/10.1074/jbc.C300012200Sugimoto H, Hamanog Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry 2003;278(15):12605–12608. doi.org/10.1074/jbc.C300012200Henao DE, Mathieson PW, Saleem MA et al. A novel renal perspective of preeclamsia: a look from the podocyte. Nephrol Dial Transplant 2007;22(5): 1477 .doi:10.1093/ndt/gf1804Henao DE, Mathieson PW, Saleem MA et al. A novel renal perspective of preeclamsia: a look from the podocyte. Nephrol Dial Transplant 2007;22(5): 1477 .doi:10.1093/ndt/gf1804Garovic V, Wagner S, Petrovic L et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22: 1136–1143. doi.org/10.1093/ndt/gfl711Garovic V, Wagner S, Petrovic L et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22: 1136–1143. doi.org/10.1093/ndt/gfl711Garovic VD, Wagner SJ, Turner ST. Urinary podocyte excretion as a marker for preeclampsia. Am J Obst Gynecol 2007; 196: 320–327. dx.doi.org/10.1016/j.ajog.2007.02.007Garovic VD, Wagner SJ, Turner ST. Urinary podocyte excretion as a marker for preeclampsia. Am J Obst Gynecol 2007; 196: 320–327. dx.doi.org/10.1016/j.ajog.2007.02.007Aita K, Etoh M, Hamada H et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Practice 2009; 112: 65–70. doi: 10.1159/000213083Aita K, Etoh M, Hamada H et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Practice 2009; 112: 65–70. doi: 10.1159/000213083Craici I M, Steven J. Wagner, Kent R. Bailey at all. Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia. Hypertension 2013;61:6 1289–1296. doi.org/10.1161/HYPERTENSIONAHA.113.01115Craici I M, Steven J. Wagner, Kent R. Bailey at all. Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia. Hypertension 2013;61:6 1289–1296. doi.org/10.1161/HYPERTENSIONAHA.113.01115Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974. doi.org/10.1136/bmj.39335.385301.BEBellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974. doi.org/10.1136/bmj.39335.385301.BERodie V, Freeman DJ, Sattar N et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy. Atherosclerosis 2004; 175(2): 189–202. doi.org/10.1016/j.atherosclerosis.2004.01.038Rodie V, Freeman DJ, Sattar N et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy. Atherosclerosis 2004; 175(2): 189–202. doi.org/10.1016/j.atherosclerosis.2004.01.038Vikse В, Lorentz M. Irgens et al. Preeclampsia and the Risk of End-Stage Renal Diseasе. Engl J Med 2008; 359: 800–809. doi.org/10.1056/NEJMoa0706790Vikse В, Lorentz M. Irgens et al. Preeclampsia and the Risk of End-Stage Renal Diseasе. Engl J Med 2008; 359: 800–809. doi.org/10.1056/NEJMoa0706790Munkhaugen J, Vikse BE. New aspects of pre-eclamsia: lessons for the nephrologist. Nephrol Dial Transplant 2009; 3 pages.doi:10.1093/ndt/gfp341Munkhaugen J, Vikse BE. New aspects of pre-eclamsia: lessons for the nephrologist. Nephrol Dial Transplant 2009; 3 pages.doi:10.1093/ndt/gfp341Bar J, Kaplan B, Wittenberg C et al. Microalbuminuria after pregnancy complicated by preeclampsia. Nephrol Dial Transplant 1999; 14: 1129–1132. doi.org/10.1093/ndt/14.5.1129Bar J, Kaplan B, Wittenberg C et al. Microalbuminuria after pregnancy complicated by preeclampsia. Nephrol Dial Transplant 1999; 14: 1129–1132. doi.org/10.1093/ndt/14.5.1129Nisell H, Lintu H, Lunell NO et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995;102: 876–881. doi.org/10.1111/j.1471-0528.1995.tb10874.xNisell H, Lintu H, Lunell NO et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995;102: 876–881. doi.org/10.1111/j.1471-0528.1995.tb10874.xAbbate M, Zoja C, Rumuzzi G. How does proteinuria cause progressive renal damage? J Am Sos Nephrol 2006; 17: 2974–2984. doi.org/10.1681/ASN.2006040377Abbate M, Zoja C, Rumuzzi G. How does proteinuria cause progressive renal damage? J Am Sos Nephrol 2006; 17: 2974–2984. doi.org/10.1681/ASN.2006040377Murakami S, Saitih M, Kubo T et al. Renal desease in woman with severe preeclampsia or gestational proteinuria. Obstet Gynaecol 2000; 96: 945–949. doi.org/10.1016/S00297844(00)01055-3Murakami S, Saitih M, Kubo T et al. Renal desease in woman with severe preeclampsia or gestational proteinuria. Obstet Gynaecol 2000; 96: 945–949. doi.org/10.1016/S00297844(00)01055-3Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24: 883–887. doi.org/10.1016/ S0272-6386(12)81055-9Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24: 883–887. doi.org/10.1016/ S0272-6386(12)81055-9Ihle BU, Long P, Oats J. Early onset preeclampsia: Recognition of underlying renal disease. Br Med J (Clin Res Ed)1987; 294:79. DOI: 10.1016/0020-7292(87)90109-3Ihle BU, Long P, Oats J. Early onset preeclampsia: Recognition of underlying renal disease. Br Med J (Clin Res Ed)1987; 294:79. DOI: 10.1016/0020-7292(87)90109-3Poon LCY, Kametas NA, Maiz N et al. First – trimestre prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812–818. doi: 10.1161/HYPERTENSIONAHA.108.127977Poon LCY, Kametas NA, Maiz N et al. First – trimestre prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812–818. doi: 10.1161/HYPERTENSIONAHA.108.127977

The authors declare that there are no conflicts of interest present.